Brief Article
Copyright ©2012 Baishideng.
World J Diabetes. Sep 15, 2012; 3(9): 161-169
Published online Sep 15, 2012. doi: 10.4239/wjd.v3.i9.161
Table 4 Summary of adverse events n (%)
Events
Vildagliptin add-on to metforminVildagliptin + metformin (SPC)Other OADs
Total adverse events77 (100.0)336 (100.0)77 (100.0)
Adverse events with suspected causal relationship134 (44.2)151 (44.9)31 (40.3)
Serious adverse events20 (26.0)118 (35.1)16 (20.8)
Serious adverse events with suspected causal relationship11 (1.3)22 (6.5)6 (7.8)
Most common adverse events (preferred terms)
Glycosylated haemoglobin increased18 (23.4)102 (30.4)26 (33.8)
Blood glucose increased11 (14.3)34 (10.1)6 (7.8)
Blood pressure increased5 (6.5)16 (4.8)9 (11.7)
Blood pressure systolic increased5 (6.5)16 (4.8)7 (9.1)
Treatment noncompliance4 (5.2)18 (5.4)1 (1.3)
Hypertension3 (3.9)13 (3.9)7 (9.1)
Selected hepatic adverse events (preferred terms)
Transaminases increased0 (0.0)2 (0.6)1 (1.3)
Alanine aminotransferase increased0 (0.0)1 (0.3)0 (0.0)
Aspartate aminotransferase increased1 (1.3)1 (0.3)0 (0.0)